There's a new choice for treating erectile dysfunction, but the question investors should be asking is whether it'll increase sales of Eli Lilly's
The ironic thing is that Eli Lilly only needed to get the approval because its drug lasts longer than its competitors'. Pfizer's
The big question is whether the new dosage will increase sales of Cialis. Sales of the drug will likely go over $1 billion for the first time in 2007, but it still trails Viagra in total sales. The drugs may make patients blind or deaf, but men are still going to take them.
Eli Lilly is going to price a one-month supply of the once-a-day dose at about the same price as eight of the tablets that last 36 hours, so it may be that patients who are having sex more than twice a week will switch to the low-dose formula without any increase in revenue.
Whether Eli Lilly can convince men and their partners who like the idea of spontaneity to switch from rival products remains to be seen. But I can't wait to see the new advertisements.
More from The Motley Fool
Is Eli Lilly and Company a Buy in 2018?
The outlook is complicated for this big pharma stock.
Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know
What's Lilly's next stage of growth? CEO Dave Ricks answered this question and more at the J.P. Morgan Healthcare Conference.
Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc.
Find out which big American pharma is best suited to provide big gains in the years to come.